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Abstract
 
2B4 is a surface molecule involved in activation of the natural killer (NK) cell–mediated cyto-
toxicity. It binds a protein termed Src homology 2 domain–containing protein (SH2D1A) or
signaling lymphocyte activation molecule (SLAM)-associated protein (SAP), which in turn has
been proposed to function as a regulator of the 2B4-associated signal transduction pathway. In
this study, we analyzed patients with X-linked lymphoproliferative disease (XLP), a severe in-
herited immunodeficiency characterized by critical mutations in the SH2D1A gene and by the
inability to control Epstein-Barr virus (EBV) infections. We show that, in these patients, 2B4
not only fails to transduce triggering signals, but also mediates a sharp inhibition of the NK-
mediated cytolysis. Other receptors involved in NK cell triggering, including CD16, NKp46,
NKp44, and NKp30, displayed a normal functional capability. However, their activating func-
tion was inhibited upon engagement of 2B4 molecules. CD48, the natural ligand of 2B4, is
highly expressed on the surface of EBV
 
1
 
 B cell lines. Remarkably, NK cells from XLP patients
could not kill EBV
 
1
 
 B cell lines. This failure was found to be the consequence of inhibitory
signals generated by the interaction between 2B4 and CD48, as the antibody-mediated disrup-
tion of the 2B4–CD48 interaction restored lysis of EBV
 
1
 
 target cells lacking human histocom-
patibility leukocyte antigen (HLA) class I molecules. In the case of autologous or allogeneic
(HLA class I
 
1
 
) EBV
 
1
 
 lymphoblastoid cell lines, restoration of lysis was achieved only by the si-
multaneous disruption of 2B4–CD48 and NK receptor–HLA class I interactions. Molecular
analysis revealed that 2B4 molecules isolated from either XLP or normal NK cells were identi-
cal. As expected, in XLP-NK cells, 2B4 did not associate with SH2D1A, whereas similar to
2B4 molecules isolated from normal NK cells, it did associate with Src homology 2 domain–
containing phosphatase 1.
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Introduction
 
X-linked lymphoproliferative disease (XLP;
 
1
 
 Mendelian in-
heritance in man [MIM] 308240) is a severe inherited im-
mune deficiency characterized by abnormal immune re-
sponses to EBV (1, 2). After EBV infection, most XLP
males succumb to fulminant infectious mononucleosis,
whereas those who survive develop lymphoma, hypo- or
dysgammaglobulinemia, and/or histiocytic infiltration lead-
ing to marrow aplasia. The overall prognosis of XLP is very
poor, with 
 
.
 
70% of affected patients dying by 10 years of
age (3). In most cases, before EBV infection, the immuno-
logical status of genotypically affected males is normal (4),
whereas expansion of CD8
 
1
 
 T cells, reduced NK cytotoxic
activity, and diminished response to delayed-type hyper-
sensitivity tests are observed after exposure to EBV (5–7).
Recently, different groups have independently identified
in XLP families mutations in a novel gene (8–10). This
gene encodes for a short intracytoplasmic protein of 128
amino acids, termed Src homology 2 domain–containing
protein (SH2D1A) or signaling lymphocyte activation mol-
ecule (SLAM)-associated protein (SAP). SH2D1A is pre-
dominantly expressed in lymphoid tissues (thymus, spleen),
and particularly in T lymphocytes (8–10). Controversial
data have been reported on the expression of SH2D1A in
B cells and B cell lines (8–10). Although the SH2D1A tran-
script has also been detected in NK cells, no information is
available on the actual presence of the encoded protein (8).
The molecular and cellular mechanisms that account for
XLP are still poorly defined. It has been proposed that the
SH2D1A protein functions as a regulator of the signal
transduction pathways initiated by at least two distinct
human surface receptors belonging to the CD2 family:
namely, signaling lymphocyte activation molecule, which
is expressed on T and B cells (9, 11), and 2B4, which is pri-
marily expressed on NK cells and on a subset of CD8
 
1
 
 T
lymphocytes (12–16). Tyrosine phosphorylation of 2B4
molecules and its association with SH2D1A or Src homol-
ogy 2 domain–containing phosphatase (SHP)-2 have been
detected in cell transfectants. In this context, it has been
suggested that binding of SH2D1A to 2B4 may prevent its
association with SHP-2. This molecular interaction may be
crucial for transducing activating signals via 2B4 (17).
However, in normal NK cells, although tyrosine phosphor-
ylation of 2B4 was observed upon treatment with sodium
pervanadate, neither SH2D1A nor SHP-2 association to
2B4 has been described so far (14). Although the role of
2B4 in T cell functions is still unknown, in NK cells the
engagement of 2B4 by specific mAbs (12–15) or by its nat-
ural ligand (i.e., CD48 [14, 18–20]) has been shown to
trigger cytolytic activity. More recently, we showed that
the NK cell triggering via 2B4 is strictly dependent upon
 
the simultaneous cross-linking of other triggering NK re-
ceptors. These data suggested that 2B4 may function as a
coreceptor in the process of NK cell activation and natural
cytotoxicity (21).
In this study, we analyzed the NK cell function in XLP
patients. Different triggering receptors including CD16
(22) and the “natural cytotoxicity receptors” (NCRs [23,
24]) NKp46 (25, 26), NKp44 (27, 28), and NKp30 (29)
were found to display normal functional capabilities. In
contrast, 2B4, upon interaction with its ligand (CD48) on
target cells, failed to activate but rather inhibited the NK
cell–mediated cytotoxicity against EBV-infected cells that
is primarily mediated via NKp46 receptor. The abnormal
function of 2B4 molecules appeared to be directly involved
in the inability of XLP-NK cells to lyse EBV-infected cells,
as mAb-mediated disruption of the 2B4–CD48 interaction
resulted in killing of EBV-infected cells.
 
Materials and Methods
 
mAbs.
 
The following mAbs were used in this study: JT3A
(IgG2a, anti-CD3); BAB281 and KL247 (IgG1 and IgM, re-
spectively, anti-NKp46); Z231 and KS38 (IgG1 and IgM, respec-
tively, anti-NKp44); KD1 and c127 (IgG2a and IgG1, respec-
tively, anti-CD16); c218 and FS280 (IgG1 and IgG2a,
respectively, anti-CD56); A6-136 (IgM, anti-HLA class I [30]);
GL183 (IgG1, anti-p58.2); EB6 (IgG1, anti-p58.1); Z199
(IgG2b, anti-NKG2A); PP35 (15, 21) and S39 (IgG1 and IgG2a,
respectively, anti-2B4); and P192 (IgG2a, anti-IRp60). Other
anti-2B4 mAbs used in this study were BAB57 (IgG1), BAB102
(IgG1), and MA344 (IgM).
D1.12 (IgG2a, anti–HLA-DR) mAb was provided by Dr. R.S.
Accolla (University of Pavia, Pavia, Italy). HP2.6 (IgG2a, anti-
CD4) mAb was provided by Dr. P. Sanchez-Madrid (Hospital de
la Princesa, Madrid, Spain). TU145 (IgM, anti-CD48) was pur-
chased from BD PharMingen.
 
Purification of PBLs and Generation of Polyclonal or Clonal NK
Cell Populations.
 
PBLs were derived from healthy or XLP do-
nors by Ficoll-Hypaque gradients and depletion of plastic-adher-
ent cells. To obtain enriched NK cells, PBLs were incubated with
anti-CD3 (JT3A), anti-CD4 (HP2.6), and anti–HLA-DR
(D1.12) mAbs (30 min at 4
 
8
 
C) followed by goat anti–mouse
coated Dynabeads (Dynal; 30 min at 4°C) and immunomagnetic
depletion (25, 29). CD3
 
2
 
4
 
2
 
DR
 
2
 
 cells were cultured on irradi-
ated feeder cells in the presence of 100 U/ml rIL-2 (Proleukin;
Chiron Corp.) and 1.5 ng/ml PHA (GIBCO BRL) to obtain
polyclonal NK cell populations or, after limiting dilution (25),
NK cell clones.
 
Flow Cytofluorimetric Analysis.
 
Cells were stained with the
appropriate mAb followed by PE- or FITC-conjugated isotype-
specific goat anti–mouse second reagent (Southern Biotechnol-
ogy Associates, Inc.). Samples were analyzed by one- or two-
color cytofluorimetric analysis (FACScan™; Becton Dickinson)
as described previously (27).
 
Cell Lines and Cytolytic Assays.
 
The following target cells
were used in this study: P815 (murine mastocytoma, Fc
 
g
 
R
 
1
 
),
EBV lymphoblastoid cell line (LCL) 721.221 target cell line
(Fc
 
g
 
R
 
2
 
HLA class I
 
2
 
CD48
 
1
 
), LCLs from patient A and from do-
nor LM, Daudi Burkitt lymphoma, SMMC hepatocarcinoma,
and MEL15 melanoma (29).
 
1
 
Abbreviations used in this paper:
 
 HRPO, horseradish peroxidase; KIR,
killer inhibitory receptor; LCL, lymphoblastoid cell line; NCR, natural
cytotoxicity receptor; ORF, open reading frame; SH2D1A, Src homol-
ogy 2 domain–containing protein; SHP, Src homology 2 domain–con-
taining phosphatase; XLP, X-linked lymphoproliferative disease. 
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Cells were tested for cytolytic activity in a 4-h 
 
51
 
Cr-release as-
say as described previously (25, 29), in the absence or presence of
various mAbs. The concentrations of the various mAbs were 10
 
m
 
g/ml for the masking experiments and 0.5 
 
m
 
g/ml for the redi-
rected killing experiments unless otherwise specified. The E/T
ratios are indicated in the text.
 
Biochemical Characterization of 2B4 Molecules.
 
20 
 
3
 
 10
 
6
 
 cells
were incubated (15 min at 20
 
8
 
C) in 1 ml PBS, pH 8 containing
250 
 
m
 
g of EZ-Link™ Sulfo-NHS-LC-LC-Biotin (Pierce Chem-
ical Co.) and washed three times in washing buffer (10 mM Tris,
pH 8, 0.14 M NaCl). Cells were then lysed in 1% NP-40 and im-
munoprecipitated with Sepharose-PA–coupled (Amersham Phar-
macia Biotech) mAbs. Samples were analyzed by discontinuous
SDS-PAGE either undigested or digested with 
 
N
 
-glycosidase F
(Boehringer) and transferred to Immobilon
 
 
 
P
 
 
 
(Millipore). After
staining with neutravidin (Pierce Chemical Co.), the Renaissance
Chemiluminescence Kit (NEN Life Science Products) was used
for detection.
 
Analysis of the 2B4 Signal Transduction Pathway.
 
Cells (10
 
8
 
)
were stimulated or not with 100 
 
m
 
M sodium pervanadate (27–
29), and 1% NP-40 lysates were immunoprecipitated with mAbs
and rabbit antiserum coupled to Sepharose-PA or Sepharose-
CNBR (Amersham Pharmacia Biotech). Samples were analyzed
in discontinuous SDS-PAGE, transferred to Immobilon
 
-
 
P
 
 
 
(Milli-
pore), and probed with the following: (a) antiphosphotyrosine
mAb (PY20-HRPO; Transduction Laboratories), (b) anti–SHP-2
phosphatase (PTP1D; Transduction Laboratories) or anti–SHP-1
phosphatase mAbs (PTP1C; Transduction Laboratories) followed
by rabbit anti–mouse horseradish peroxidase (HRPO; Dako), and
(c) anti-SH2D1A rabbit antiserum followed by donkey anti–rab-
bit HRPO (Amersham Pharmacia Biotech). The Renaissance
Chemiluminescence Kit (NEN Life Science Products) was used
for detection.
The anti-SH2D1A rabbit antiserum was produced by Euro-
gentec. The 12–amino acid KLH-conjugated C-QGTTGIRED-
PDV peptide was used.
 
Reverse Transcriptase PCR Analysis of 2B4 and SH2D1A Tran-
scripts in XLP-NK Cells.
 
Total RNA was extracted from the
polyclonal NK population and clones of XLP patients using
RNA-CLEAN (TIB MOLBIOL). cDNA synthesis was per-
formed using oligo-dT priming. Primers used for cDNA amplifi-
cation of complete human 2B4 open reading frame (ORF; 1197
bp) were the following: 5
 
9
 
-CCTGGCCCCTCTGTCCTG
(PP35 ORF up) and 5
 
9
 
-TCCTGTGCCGTCATCCACTG
(PP35 ORF down). Amplification was performed for 30 cycles
(30 s at 94
 
8
 
C, 30 s at 60
 
8
 
C, and 30 s at 72°C), followed by a
7-min incubation at 72
 
8
 
C. The SH2D1A cDNA (632 bp) was
amplified using the following primers: 5
 
9
 
-CAGCGGCATCTC-
CCTTG (SH2D1A-3 ORF forward) and 5
 
9
 
-TTTCAAA-
GCTCCTCACTATG (SH2D1A-4 ORF reverse). Amplifica-
tion was performed for 30 cycles (30 s at 94
 
8
 
C, 30 s at 55
 
8
 
C, and
30 s at 72
 
8
 
C), followed by a 7-min incubation at 72
 
8
 
C. Both
PCR reactions were performed using AmpliTaq (PE Biosystems).
PCR product obtained from NK cells was subcloned into
pcDNA 3.1 vector (Invitrogen) and sequenced. DNA sequencing
was performed using a d-Rhodamine Terminator Cycle Sequenc-
ing Kit and a 377 Applied Biosystems Automatic Sequencer (PE
Biosystems).
 
Results
 
Characterization of SH2D1A Mutations in Two XLP Pa-
tients.
 
Two XLP families have been analyzed (Fig. 1 a). In
family A, the proband (hereafter referred to as patient A) is
a 3-yr-old, EBV-seronegative child who was identified as
genotypically affected by a mutation at the SH2D1A locus
represented by a G to T nucleotide change at the transla-
tion initiation codon (ATG to ATT), leading to a me-
thionine to isoleucine amino acid change. The same muta-
tion was identified in XLP obligate carriers from the same
family, in which several males died of fulminant hepatitis or
leukemia after EBV infection. The immunological pheno-
type in patient A was normal apart from slightly reduced
IgG1 and IgG3 serum levels.
In family B, the proband is an EBV-seropositive 56-yr-
old male who was treated for a histiocytic lymphoma at 14
years of age and developed severe hepatitis at 21 years. Be-
cause of recurrent episodes of pneumonia and sinusitis, at
36 years of age he was further investigated and found to
be hypogammaglobulinemic. Mutation analysis at the
SH2D1A locus revealed a C to T nucleotide change at po-
sition 163, leading to premature termination at codon 55.
Of patient B’s two nephews, the elder developed severe
hepatitis at 27 years of age, and the younger was diagnosed
with EBV-related non-Hodgkin lymphoma at 3 years of
age, and since then suffered from recurrent upper and
lower respiratory tract infections. Both patient B nephews
carry the same mutation at codon 55.
PBLs of the two patients were analyzed by indirect im-
munofluorescence and FACS
 
®
 
 analysis for the expression
of cell surface markers including CD3, CD56, CD20, and
2B4. Although in patient A the percentage of positive cells
was within a normal range (13, 15), in patient B the per-
centage of 2B4
 
1
 
 cells was markedly higher than in control
individuals (Fig. 1 b). Double fluorescence analysis of PBLs
derived from patient B revealed that most CD3
 
1
 
 T cells
were 2B4
 
1
 
. All of these CD3
 
1
 
2B4
 
1
 
 cells were CD8
 
1
 
,
whereas the small CD3
 
1
 
2B4
 
2
 
 subset (
 
,
 
5%) was CD4
 
1
 
.
Remarkably, all CD8
 
1
 
 cells (including both CD8
 
bright
 
 T
cells and CD8
 
dull
 
 NK cells) were 2B4
 
1
 
. It is of note that in
normal individuals (see the representative individual A.M.
in Fig. 1 c), a fraction of CD8
 
bright
 
 cells is consistently 2B4
 
2
 
(13–15). Note also that in donor A.M., unlike in patient B,
a low percentage of CD3
 
1
 
 cells expressed 2B4.
 
Expression and Function of Triggering Surface Molecules in
NK Cells from XLP Patients.
 
To assess the transcription of
SH2D1A gene in NK cells isolated from the XLP patients
A and B, we performed reverse transcriptase PCR analysis
of RNA extracted from polyclonal NK cell populations.
The sequence analysis of cloned PCR products showed the
presence of two cDNAs, one corresponding to the full-
length SH2D1A transcript and the other to the previously
described coding sequence lacking 55 nucleotides in exon
3, termed SH2D1A
 
D
 
55 or hSAP
 
D
 
55 (9). Both transcripts
carried the expected mutations (described above; data not
shown). Using a similar approach, we analyzed NK cells
derived from healthy donors. Both unmutated SH2D1A
and SH2D1A
 
D
 
55 transcripts could be identified.
The same polyclonal NK cell populations were analyzed
for the surface expression of 2B4 and of several other NK
cell markers. Expression of the HLA class I–specific inhibi- 
340
 
Inhibitory 2B4 Molecules Prevent NK Cell Function in XLP
 
tory receptors, including killer inhibitory receptors (KIRs)
and CD94/NKG2A, was comparable to that of healthy do-
nors (not shown). Similarly, analysis of triggering receptors
including CD16 and NCRs (NKp46, NKp44, and NKp30
[23–29]) as well as 2B4 did not reveal substantial differences
compared with normal controls (not shown). These data
are in agreement with those obtained in fresh PBLs, and
suggest that the lack of SH2D1A protein does not affect the
surface expression (or density) of 2B4 in human NK cells.
XLP-NK cells were then assessed for cytolytic activity in
a redirected killing assay against murine (Fc
 
g
 
R
 
1
 
) P815 tar-
get cells. As shown in Fig. 2 a, the NK-mediated spontane-
ous lysis of P815 was comparable to that mediated by NK
cells derived from healthy donors. Moreover, addition of
anti-CD16 or anti-NCR mAbs resulted in the enhance-
ment of cytolytic activity (25, 27, 29). On the other hand,
unlike in normal NK cells (15, 21), both the spontaneous
and the CD16- or NCR-induced lysis of P815 was sharply
inhibited by anti-2B4 mAb in XLP-NK cells (Fig. 2 a).
These results indicate that in XLP-NK cells, cross-linking
of 2B4 molecules results in inhibition of cytolytic activity
induced via different triggering receptors.
 
2B4 Inhibits the NK-mediated Killing of EBV B Cell Lines
in XLP Patients.
 
A panel of 
 
.
 
50 NK cell clones derived
from patient A and two polyclonal NK cell populations de-
rived from patients A and B were analyzed for their ability
to lyse the LCL 721.221 EBV cell line and the Daudi Bur-
kitt lymphoma (31). It is of note that both of these target
Figure 1. Family pedigrees and cytofluo-
rimetric analysis of PBLs from two XLP pa-
tients. (a) Pedigrees of family A and family
B with XLP. The arrows indicate index
cases. Mutation analysis at the SH2D1A lo-
cus confirmed the diagnosis of XLP in pa-
tient IV,1 from family A and in patients II,1,
III,1, and III,2 from family B. In both pedi-
grees, dotted circles identify carrier females,
as diagnosed by mutation analysis at the
SH2D1A locus. (b) Freshly isolated PBLs
derived from XLP patients A and B were
analyzed by immunofluorescence and
FACS® analysis using mAbs specific for the
indicated molecules, followed by isotype-
specific PE-conjugated goat anti–mouse
second reagent. Cells incubated with the
second reagent alone represent the negative
control (CTR). Percentages of positive cells
are indicated in each square. (c) PBLs de-
rived from XLP patient B and from a
healthy donor (A.M.) were analyzed by
two-color immunofluorescence and FACS®
analysis with anti-2B4 mAb in combination
with anti-CD3, anti-CD4, or anti-CD8
mAbs. Isotype-specific FITC- or PE-conju-
gated goat anti–mouse was used as second
reagent. The contour plots were divided
into quadrants representing unstained cells
(lower left), cells with only red fluorescence
(upper left), cells with red and green fluo-
rescence (upper right), and cells with only
green fluorescence (lower right). 
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cells are HLA class I
 
2
 
 and express large amounts of CD48
(i.e., the ligand for 2B4 [14, 18–20]). Because of the lack of
HLA class I expression, both targets were lysed by NK cells
from healthy donors (Fig. 2 b), but they were resistant to
lysis by XLP-NK cells. However, upon mAb-mediated
masking of 2B4 molecules, an efficient restoration of lysis
of both LCL 721.221 (Fig. 2 b) and Daudi (not shown)
cells could be detected. These data suggested that in XLP
patients, the 2B4-mediated recognition of CD48 on target
cells may induce a strong inhibitory effect on the NK cell–
mediated cytotoxicity.
 
 
 
In agreement with this concept, the
cytolytic activity of XLP-NK cell clones was also restored
by mAb-mediated masking of CD48 molecules (not
shown). On the other hand, XLP-NK cells could effi-
ciently lyse some NK-susceptible tumor cell lines, includ-
ing the HLA class I
 
2
 
 SMMC (hepatocarcinoma [31]) and
the MEL15 (melanoma [31]; data not shown). Remark-
ably, unlike LCL 721.221 or Daudi, these tumors do not
express CD48 molecules (not shown). Taken together,
these data imply that CD48 also represents a ligand for the
“inhibitory” 2B4 molecules of XLP-NK cells. In addition,
they show that upon disruption of the 2B4–CD48 inhibi-
tory interactions (either by masking the receptor or the
ligand), NK cells from XLP patients display a cytolytic ac-
tivity comparable to that of normal NK cells.
 
2B4 Inhibits Killing of EBV-infected Cells by Interfering with
NKp46-mediated NK Cell Activation.
 
Previous studies in-
dicated that in healthy individuals, lysis of LCL 721.221
target cells is primarily mediated by triggering signals deliv-
ered via the NKp46 NCR (31). In agreement with these
data, killing of LCL 721.221 cells by normal NK cell clones
was sharply inhibited by mAb-mediated masking of
NKp46. As reported above, NKp46 also displays a normal
triggering capability in XLP-NK cells. Thus, we further
evaluated whether lysis of LCL 721.221 target cells (detect-
able upon mAb-mediated masking of 2B4) was also depen-
dent upon NKp46 in XLP. To this end, XLP-NK cells
were assessed for cytotoxicity against LCL 721.221 target
cells either in the presence of anti-2B4 mAb or in the pres-
ence of both anti-2B4 and anti-NKp46 mAbs. As shown in
Fig. 2 c, upon masking of both receptors, target cell lysis
was sharply inhibited.
The availability of an LCL from XLP patient A allowed
us to analyze the ability of NK cells to kill autologous
EBV
 
1
 
 target cells. Unlike LCL 721.221 or Daudi, patient
A LCLs expressed HLA class I molecules. Therefore, the
cytolytic activity of XLP-NK cells was evaluated in the
presence of appropriate anti–HLA class I mAbs (of IgM
isotype; [30]). As shown in Fig. 3, under these experimen-
tal conditions, we could not detect restoration of lysis, as it
occurs with normal NK cells. These data suggested the ex-
istence of additional inhibitory signals, possibly mediated
by the interaction between 2B4 and CD48. Indeed, lysis of
autologous LCLs could be efficiently reconstituted only
Figure 2. Engagement of 2B4 inhibits the
NK-mediated cytolytic activity in XLP patients.
(a) Polyclonal NK cell populations derived from
XLP patients A and B or from a normal control
were analyzed for cytolytic activity in a redi-
rected killing assay against the FcgR1 P815 tar-
get cell line in the absence or presence of mAbs
specific for the indicated molecules. The E/T ra-
tio used was 8:1. All the mAbs used in this exper-
iment were of the IgG1 isotype. (b) Polyclonal
NK cell populations derived from a normal con-
trol or from XLP patients A and B and four rep-
resentative NK cell clones derived from XLP
patient A were analyzed against the
EBV1CD481HLA class I2 LCL 721.221 target
cell line in the absence (white bars) or presence
(black bars) of anti-2B4mAb. The E/T ratio used
was 3:1. (c) Two representative NK cell clones
derived from XLP patient A were analyzed
against the EBV1HLA class I2 LCL 721.221 tar-
get cell line in the absence of mAb (j) or in the
presence of anti-2B4 mAb alone (s), or in com-
bination with anti-NKp46 mAb (,). The E/T
ratios used are indicated.342 Inhibitory 2B4 Molecules Prevent NK Cell Function in XLP
when both the 2B4–CD48 and KIR–HLA class I interac-
tions were simultaneously disrupted by the addition of spe-
cific mAbs (Fig. 3). In conclusion, these data indicate that
in XLP patients, the altered function of 2B4 deeply affects
the ability of NK cells to kill both autologous and alloge-
neic EBV-transformed B cells.
Molecular Characterization of 2B4 in XLP-NK Cells. Re-
cently, Southern blot analysis of human DNA indicated that
human 2B4 is encoded by a single gene of z25 kb (16). This
finding suggests that the inhibitory function of 2B4 in XLP-
NK cells is not consequent to the transcription of a different
2B4-encoding gene. To confirm this hypothesis, the expres-
sion of the 2B4 transcript was analyzed by reverse tran-
scriptase PCR in polyclonal NK cells derived from the XLP
patients A and B or from healthy donors. Sequence analysis
of the amplified cDNAs revealed, in all samples analyzed, the
presence of two major products: the first corresponded to the
full-length 2B4 molecule (16–18, 20, 21), and the second to
a sequence identical to 2B4 but lacking the IgC2 domain
(1D-2B4; sequence data available from EMBL/GenBank/
DDBJ under accession no. AJ245376). Remarkably, COS7
cells transiently transfected with the 1D-2B4 construct were
not stained by any of the five available anti-2B4 mAbs (not
shown). Finally, a poorly represented transcript referred to as
sh2B4 (sequence data available at EMBL/GenBank/DDBJ
under accession no. AJ245377) was detected in NK cell
clones derived from both XLP patients and healthy donors.
The sh2B4 is characterized by an insertion of 140 bp and en-
codes a polypeptide of 329 amino acids identical to 2B4 in
the first 320 amino acids. This cDNA is likely to result from
a splicing error, as the extra 140-bp sequence contains a con-
sensus sequence for an acceptor splice site. Being detectable
also in normal donors, sh2B4 is unlikely to be responsible for
the inhibitory functions of 2B4 in XLP patients. Along this
line, previous studies indicated that unlike in mice (32), in
humans only a single 2B4 molecule is expressed at the cell
surface (16).
Biochemical Characterization of 2B4 Molecular Complex in
Normal and XLP-NK Cells. The cytoplasmic tail of 2B4 is
characterized by four tyrosine-based motifs (TxYxxI/V;
reference 14). 2B4 tyrosine phosphorylation upon pervana-
date treatment has been demonstrated previously in both
normal NK cells (14) and cell transfectants (17). Experi-
ments performed in 2B4 cell transfectants suggested that it
may associate with SH2D1A and SHP-2 (17). Moreover, it
has also been suggested that SH2D1A competes with SHP-2
for binding to 2B4. However, in normal NK cells, neither
SH2D1A nor SHP-2 association to 2B4 could be detected
(14). Thus, controversial information existed on the molecu-
lar mechanisms that account for 2B4 activating function.
We therefore performed a comparative analysis of 2B4 and
associated molecules in normal or XLP-NK cells.
To this end, polyclonal NK cell populations were first
surface labeled with biotin, and cell lysates were immuno-
precipitated with anti-2B4 mAb. 70-kD surface molecules
(14–18) were immunoprecipitated from both normal and
XLP-NK cells. Moreover, treatment with N-glycosidase re-
vealed an identical protein backbone of z40 kD (Fig. 4 a).
Figure 3. Analysis of XLP-NK cell–mediated cytolytic activity against
autologous LCLs. Polyclonal NK cell populations derived from XLP pa-
tient A or from a healthy donor (LM) were analyzed against LCLs derived
from patient A or from donor LM in the absence or presence of mAbs
specific for the indicated molecules. The E/T ratio used was 5:1.
Figure 4. Biochemical analysis of 2B4 molecules in normal and XLP-
NK cells. (a) Polyclonal NK cell populations derived from healthy do-
nors (NK) or XLP-patients (XLP-NK) were surface labeled with biotin
and immunoprecipitated with anti-2B4 (S39 mAb) or anti-NKG2A
(Z199 mAb). Samples were treated (1) or not (2) with N-glycosidase F
and analyzed in an 8% SDS-PAGE under reducing conditions. (b) Anti-
2B4 or anti-CD56 (FS280 mAb, negative control) immunoprecipitates
were obtained from NK or XLP-NK cell populations either untreated
(2) or treated (1) with sodium pervanadate. Samples were analyzed in
an 11% SDS-PAGE under reducing conditions and probed with an-
tiphosphotyrosine (anti-P-Tyr) mAb. Molecular mass markers (kD) are
indicated on the right.343 Parolini et al.
Next, 2B4 molecules were immunoprecipitated from
cells treated or not with sodium pervanadate. Samples were
analyzed in SDS-PAGE and probed with antiphosphoty-
rosine mAb. As shown in Fig. 4 b, under the experimental
conditions used, a low degree of 2B4 tyrosine phosphoryla-
tion was consistently detected in IL-2–cultured polyclonal
NK cell populations derived from both healthy donors and
XLP patients. Notably, sodium pervanadate treatment led
to strong increments of 2B4 tyrosine phosphorylation both
in normal and XLP-NK cells, although in XLP-NK cells
phosphorylation appeared to be of lower density.
2B4 immunoprecipitates, obtained as described in the leg-
end to Fig. 4 b, were probed with anti-SH2D1A antise-
rum. As shown in Fig. 5 a and in line with previous reports
on cell transfectants (17), treatment with pervanadate led to
the association of the 2B4 receptor with the SH2D1A mol-
ecule in normal NK cells. On the other hand, in XLP-NK
cells, neither SH2D1A protein nor 2B4–SH2D1A associa-
tion could be detected, as expected.
2B4 immunoprecipitates, obtained as indicated above,
were subsequently probed with mAb specific for SHP-2 or
SHP-1 cytoplasmic phosphatases. Negative and positive
controls were represented by NK cell lysates immunopre-
cipitated with mAbs specific for NKp46 (25) or IRp60 (33)
molecules, respectively. NKp46 is an NK-specific receptor
that transduces activating signals via the association with
the CD3z/FceRIg molecules (23, 27, 28). IRp60 is an
immunoreceptor tyrosine-based inhibition motif (ITIM)-
bearing inhibitory receptor, expressed by all human NK
cells, that associates with SHP-1 and SHP-2 (33). No 2B4–
SHP-2 association could be detected in normal and XLP-
NK cells (Fig. 5, b and c). However, SHP-1 phosphatase
was detected in 2B4 immunoprecipitates obtained from
both untreated and treated cells. Remarkably, both in nor-
mal and in XLP-NK cells, sodium pervanadate treatment
did not result in increments of the 2B4-associated SHP-1
(Fig. 5, b and c) whereas in control IRp60 immunoprecip-
itates, this treatment led to a strong increment of IRp60-
associated SHP-1. The finding that SHP-1 also associates
with 2B4 in untreated cells could be justified by the low
degree of 2B4 tyrosine phosphorylation detected in IL-2–
cultured normal or XLP-NK cells used in these experi-
ments (Fig. 4 b).
Discussion
In this study, we show that an altered function of 2B4
molecules may contribute to the inability of XLP patients
to control EBV infections. In these patients, 2B4 functions
as an inhibitory rather than activating receptor, and this al-
tered function causes a severe impairment of the NK cell–
mediated cytotoxicity against EBV-infected cells.
Previous studies using cell transfectants (17) provided ev-
idence that human 2B4 can associate to SH2D1A mole-
cules. Because XLP disease is characterized by mutations in
the SH2D1A-encoding gene (8–10), the aim of this study
was to analyze whether 2B4 molecules had an altered func-
tion in XLP patients. In agreement with previous data ob-
tained in cell transfectants, we show that in NK cells
derived from healthy donors, SH2D1A associates with
Figure 5. Biochemical characterization of 2B4-associated molecules in normal
and XLP-NK cells. (a) NK or XLP-NK cell populations, either untreated (2) or
treated (1) with sodium pervanadate, were immunoprecipitated with anti-2B4
(S39 mAb), anti-IRp60 (P192 mAb, isotype-matched negative control), or anti-
SH2D1A antiserum. Samples were analyzed in a 14% SDS-PAGE under reduc-
ing conditions and probed with anti-SH2D1A antiserum. (b) 2B4, IRp60 (posi-
tive control), and NKp46 (BAB281 mAb, negative control) molecules were se-
quentially immunoprecipitated from normal polyclonal NK cell populations
either untreated (2) or treated (1) with sodium pervanadate. Identical samples
were divided, analyzed in 7% SDS-PAGE under reducing conditions, and probed
with either anti–SHP-2 (left) or anti–SHP-1 (right) mAbs. Sepharose-PA pre-
clearing on treated cells (/) is also shown. (c) Anti-2B4, anti–SHP-2, or anti–SHP-1 immunoprecipitates were derived from XLP-NK cell populations ei-
ther untreated (2) or treated (1) with sodium pervanadate. Identical samples were divided, analyzed in 7% SDS-PAGE under reducing conditions, and
probed with either anti–SHP-2 (left) or anti–SHP-1 (right) mAbs. Molecular mass markers (kD) are indicated. Arrows indicate SH2D1A, SHP-2, and
SHP-1 molecules. The first lanes in b and c were loaded with the S39 (2B4-specific) mAb alone as control.344 Inhibitory 2B4 Molecules Prevent NK Cell Function in XLP
phosphorylated 2B4 molecules. In contrast, in XLP-NK
cells, SH2D1A molecules were missing, and consequently
they did not associate with 2B4. In patient A, the lack of
functional SH2D1A proteins was consequent to a mutation
in the ATG initiation codon, whereas in patient B, a non-
sense mutation at codon 55 resulted in a truncated product
characterized by an incomplete SH2 domain. Cytofluori-
metric analysis indicated that lack of SH2D1A did not af-
fect the levels of surface expression of 2B4 molecules. Both
biochemical and molecular analysis revealed that 2B4 mol-
ecules isolated from normal or XLP-NK cells were identi-
cal. Importantly, 2B4 was found to associate with the SHP-1
phosphatase in both normal and XLP-NK cells. Whether
SHP-1 is responsible for delivering the 2B4-mediated in-
hibitory signals in XLP-NK cells lacking SH2D1A mole-
cules is under investigation. A direct demonstration that the
signaling pathway initiated by 2B4 is dramatically altered in
XLP-NK cells was obtained by several functional studies.
Thus, cross-linking of 2B4 resulted in the generation of in-
hibitory signals that blocked the NK-mediated cytolysis.
This inhibitory effect affected not only the spontaneous cy-
totoxicity but also the NK cell activation induced via
CD16 or NCRs. These data suggested that 2B4 molecules
could be involved in the inability of XLP patients to mount
an efficient immune response against EBV infections. More
direct evidence that this may represent a major physio-
pathological mechanism in XLP was provided by the anal-
ysis of EBV-infected LCLs. LCLs express relatively high
amounts of CD48 (i.e., the natural ligand of 2B4 molecules
[18–20]). We hypothesized that 2B4-mediated recognition
of CD48 molecules could result in inhibition of the XLP-
NK cell–mediated killing of EBV-infected B cells. Indeed,
XLP-NK cells were unable to kill the HLA class I2 EBV B
cell lines LCL 721.221 and Daudi. This was consequent to
a 2B4-mediated inhibitory effect, as cytolytic activity could
be restored upon mAb-mediated disruption of the 2B4–
CD48 interaction. The cytolytic activity of XLP-NK cells
could also be analyzed against an autologous EBV1 LCL
expressing HLA class I molecules. In this case, only the si-
multaneous mAb-mediated disruption of both HLA–KIR
and 2B4–CD48 interactions allowed a complete recovery
of cytotoxicity. Downregulation of HLA class I during
EBV infection has been reported previously in different
studies (34–36). In normal individuals, HLA class I down-
regulation would allow NK cells to kill EBV-infected cells
(30). However, in XLP patients, clearance of HLA-defi-
cient EBV-infected cells would be impaired because of the
occurrence of inhibitory rather than activating interactions
between 2B4 and CD48. Thus, it appears conceivable that
the altered 2B4 function may contribute to the inefficient
control of EBV1 B cells in XLP-patients. Along this line,
although not shown, preliminary data suggest that in XLP
patients, 2B4 may also negatively regulate T cell–mediated
responses. Therefore, it is possible that specific CTL re-
sponses against EBV1 B cells may also be impaired by a
molecular mechanism similar to that responsible for NK
cell dysfunction. Altogether, the altered function of 2B4
may account for a general inability of different cytolytic ef-
fector cells to control EBV infections. This will occur both
when infected cells express HLA class I (because of an im-
pairment of CTLs) and when downregulation of HLA class
I had occurred (because of an impairment of NK cells).
Our data may have relevant therapeutic implications.
XLP has a dismal prognosis: although bone marrow trans-
plantation represents the only form of permanent cure, it
gives optimal results only if performed before EBV infec-
tion. In contrast, antiviral drugs, intravenous immunoglob-
ulins, and B cell–specific mAbs have been used with mod-
est results in the treatment of overt lymphoproliferative
disease in XLP patients. Our data suggest that administra-
tion of anti-2B4 antibody could represent a novel form of
treatment that could help to control lymphoproliferation
while preparing for bone marrow transplantation.
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